|
HLA-DRB1
|
Refractory anemias
|
0.100 |
Biomarker |
BEFREE |
Autoantibodies, HAQ and ESR at baseline, symptom duration before diagnosis, and HLA-DRB1 status had influence on clinical course and development of structural joint damage in Colombian RA patients.
|
27041382 |
2016 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
Biomarker |
BEFREE |
PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study.
|
23577190 |
2013 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
GeneticVariation |
BEFREE |
Because the HLA-DRB1*15 haplotype does not predominate in the Greek population, we investigated the frequency of HLA-DRB1 alleles among 114 patients of Greek origin suffering from various types of MDS: 36 refractory anemia (RA), 24 refractory anemia with ringed sideroblasts (RARS), 19 refractory anemia with excess of blasts (RAEB), 14 refractory anemia with excess of blasts in transformation (RAEB-t), 14 chronic myelomonocytic leukemia, and 7 hypoplastic MDS patients.
|
22244918 |
2012 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
Biomarker |
BEFREE |
RA patients (n=333) and controls (n=490) from the Cree/Ojibway NAN population in Central Canada were HLA-DRB1 typed and tested for 21 single-nucleotide polymorphisms (SNPs) that have previously been associated with RA, including PTPN22, TRAF1-C5, CTLA4, PADI4, STAT4, FCRL3, CCL21, MMEL1-TNFRSF14, CDK6, PRKCQ, KIF5A-PIP4K2C, IL2RB, TNFAIP3, IL10-1082G/A and REL.
|
21614018 |
2011 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
Biomarker |
BEFREE |
The results suggest that HLA-DRB1 SE presence may favourably affect the outcome of leflunomide monotherapy in an unselected group of RA patients with an active disease and naive to leflunomide.
|
18032542 |
2007 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
GeneticVariation |
BEFREE |
However, there was no linkage observed from TAP1/TAP2 gene polymorphisms and HLA-DRB1*04 between RA patients and healthy controls.
|
14749980 |
2004 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
Biomarker |
BEFREE |
Furthermore, it has been reported that most patients with AA and refractory anemia (RA) who carry HLA-DRB1*15 and show a good response to immunosuppressive therapies have an expanded population of GPI-deficient clones.
|
12627844 |
2003 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
GeneticVariation |
BEFREE |
Molecular subtyping of HLA-DRB1*04 alleles in RA patients showed strongest association with highest relative risk with DRB1*0404.
|
12793199 |
2003 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
GeneticVariation |
BEFREE |
We observed a significant increase in the frequency of the DRB1*07 allele in severe RA patients in relation to the non-severe RA group (p = 0.02, OR = 5.65, 95% CI = 0.95-43.05).
|
12846056 |
2003 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
Biomarker |
BEFREE |
Molecular subtyping of DRB 1*04 in RA patients showed strongest association with highest relative risk with DRB 1*0405, followed by DRBI*0401.
|
9157087 |
1996 |
|
HLA-DRB1
|
Refractory anemias
|
0.100 |
GeneticVariation |
BEFREE |
Homozygosity for the HLA-DRB1*0401 allele was a characteristic finding for RA patients with major organ involvement.
|
1602009 |
1992 |